Atreca, Inc.
BCELDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001532346
Atreca, Inc. was delisted in 2024; its insiders filed their last Form 4 on Apr 17, 2024; 43 institutions reported holding it in 13F filings for Q4 2023, worth $1.24M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 43
- Q4 2023, −2 vs. previous quarter
- 13F value
- $1.24M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding BCEL, Q4 2023
No superinvestor reported holding BCEL at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Atreca, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2024 (view filing)7:36 PM ET | Apr 11 | 6 daysLate | Orwin John APRESIDENT & CEO | PPurchaseSeries A Junior Preferred Stock | +1 | $0.01 | +$0.01 | New position1 after | |
| Apr 3, 2024 (view filing)9:50 PM ET | Apr 1 | 2 days | Serafini TitoDirector | SSaleClass A Common Stock | −20.8K | $0.07 | −$1.46K | −32.3%43.6K after | |
| Apr 3, 2024 (view filing)9:37 PM ET | Sep 1, 2023 | 215 daysLate | Orwin John APRESIDENT & CEO | SSaleClass A Common Stock | −23.0K | $0.3746 | −$8.60K | −22.8%77.5K after | |
| Apr 3, 2024 (view filing)9:35 PM ET | Sep 1, 2023 | 215 daysLate | Serafini TitoDirector | SSaleClass A Common Stock | −8.39K | $0.3746 | −$3.14K | −11.5%64.4K after | |
| Apr 3, 2024 (view filing)9:33 PM ET | Sep 1, 2023 | 215 daysLate | Courtney PhillipsGENERAL COUNSEL & SECRETARY | SSaleClass A Common Stock | −7.06K | $0.3746 | −$2.65K | −12.3%50.4K after | |
| Oct 23, 2023 (view filing)4:49 PM ET | Oct 19 | 4 days | Baker Julian and 3 othersOther: Former 10% Owner | SSaleClass A common stock | −274.7K | $0.4025 | −$110.6K | −8.5%2.97M after | 2 lots |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −5.49K | $0.95 | −$5.21K | −7.0%72.8K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Cross HerbChief Financial Officer | SSaleClass A Common Stock | −5.49K | $0.95 | −$5.21K | −7.0%72.8K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Gould Stephen EChief Scientific Officer | SSaleClass A Common Stock | −4.08K | $0.95 | −$3.87K | −12.5%28.4K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Courtney PhillipsGeneral Counsel & Secretary | SSaleClass A Common Stock | −4.08K | $0.95 | −$3.87K | −6.6%57.5K after |
Top 10 13F holders, Q4 2023
The largest institutional positions in Atreca, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Boxer Capital, LLC | 2,202,333 | $290.7K | 0.01% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,177,499 | $287.4K | 0.00% | −1,355,261−38.4% | Reduced |
| Vanguard Group Inc | 909,300 | $120.0K | 0.00% | −419,623−31.6% | Reduced |
| Bill & Melinda Gates Foundation | 912,642 | $118.6K | 0.13% | 00.0% | Unchanged |
| BlackRock Inc. | 637,974 | $84.2K | 0.00% | −547,684−46.2% | Reduced |
| Redmile Group, LLC | 442,653 | $58.4K | 0.00% | 00.0% | Unchanged |
| Aisling Capital Management LP | 387,653 | $51.2K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 356,024 | $47.0K | 0.00% | +14,100+4.1% | Added |
| Geode Capital Management, LLC | 295,471 | $39.0K | 0.00% | +32,548+12.4% | Added |
| HRT Financial LP | 206,842 | $27.0K | 0.00% | +206,842 | New |